Marquette Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Marquette Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.4K	Buy	45 +3	+7%	+$1.33K	﹤0.01%	222
2026 Q1	$18.8K	Hold	42	–	–	﹤0.01%	167
2025 Q4	$19K	Buy	42 +10	+31%	+$4.31K	﹤0.01%	163
2025 Q3	$12.5K	Buy	+32	New	+$13.4K	﹤0.01%	190
2024 Q1	–	Sell	-59	Closed	-$24K	–	209
2023 Q4	$24K	Sell	59 -2	-3%	-$739	﹤0.01%	155
2023 Q3	$21.2K	Sell	61 -17	-22%	-$5.95K	0.01%	169
2023 Q2	$27.4K	Buy	+78	New	+$26.3K	0.01%	168
2019 Q2	–	Sell	-36	Closed	-$7K	–	292
2019 Q1	$7K	Buy	+36	New	+$6.65K	﹤0.01%	269

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Marquette Asset Management's VRTX Position: Q2 2026 in Review

Marquette Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.1% in Q2 2026, buying an estimated $1.33K and bringing the position to 45 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #222.

Marquette Asset Management first reported a position in VRTX in Q1 2019 and has held it in 8 quarters since. The position peaked at $27.4K in Q2 2023. 296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Marquette Asset Management held 45 shares of Vertex Pharmaceuticals worth $22.4K as of Q2 2026.
Marquette Asset Management bought 3 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.33K.
Vertex Pharmaceuticals made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #222 holding.
Marquette Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 8 quarters since.
Marquette Asset Management's Vertex Pharmaceuticals position peaked at $27.4K in Q2 2023.
296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.